Stockscreener 앱 받기
3.81
15.71%
-0.71
시간 외 거래:
3.91
0.10
+2.62%
전일 마감가:
$4.52
열려 있는:
$4.095
하루 거래량:
5.17M
Relative Volume:
70.51
시가총액:
$35.28M
수익:
$2.09M
순이익/손실:
$-30.04M
주가수익비율:
-1.1657
EPS:
-3.2685
순현금흐름:
$-27.57M
1주 성능:
+69.33%
1개월 성능:
+10.76%
6개월 성능:
-52.32%
1년 성능:
-46.03%
1일 변동 폭
$3.53
$4.1399
1주일 범위
$2.30
$7.45
52주 변동 폭
$2.13
$13.13
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.81 | 22.96M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed Inc. Files Form 8-K with SEC – Company Information, Address, and Common Stock Details - Minichart
Why did CRVO stock crash 22% in pre-market trading today? - MSN
CervoMed Posts Updated Investor Presentation and Business Overview - TipRanks
CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com - Investing.com India
Cervomed Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - marketscreener.com
CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake - Stock Titan
Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal - Stock Titan
CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings - Stock Titan
CRVO: Advancing neflamapimod to phase III in DLB, with strategic partnership and strong clinical data - TradingView
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - 富途牛牛
CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Yahoo Finance
CervoMed Inc. (CRVO) Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Progress ContinuesEPS Revision Trend - newsline.com
CervoMed Inc. (CRVO) Surges 8.44%: Testing Key Resistance at $2.56TWAP Entry - newsline.com
CervoMed Inc. (CRVO) Gains 8.4%: Support Holds as Stock Approaches Key ResistanceBearish Sentiment - newsline.com
CervoMed (CRVO) director Frank Zavrl receives grant of 8,150 stock options - Stock Titan
CervoMed (CRVO) awards 8,150 stock options to new board director - Stock Titan
CervoMed (CRVO) grants director David Quigley options on 8,150 shares - Stock Titan
[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan
CervoMed (CRVO) director receives options for 8,150 shares at $2.91 strike - Stock Titan
CervoMed (CRVO) director Sylvie Gregoire receives 8,150-share stock option award - Stock Titan
CervoMed (CRVO) director and 10% owner granted 8,150 stock options at $2.91 - Stock Titan
CervoMed (CRVO) director and CEO’s spouse granted 8,150 stock options - Stock Titan
CRVO Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Development PhaseEarnings Call Q&A - newsline.com
CervoMed (CRVO) Secures $10.5M from Private Placement - GuruFocus
CervoMed (CRVO) Secures $10.5 Million from Private Placement - GuruFocus
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today? - Asianet Newsable
CervoMed stock falls 15% after $10.5M financing announced By Investing.com - Investing.com South Africa
CervoMed stock falls 15% after $10.5M financing announced - Investing.com
CervoMed Announces Private Placement to Advance Neurology Pipeline - TipRanks
CervoMed raises $10.5 million in private placement financing - Investing.com
CervoMed : Corporate Presentation (54c99e) - marketscreener.com
CervoMed raises $10.5 million in private placement financing By Investing.com - Investing.com Canada
CervoMed Secures $10.5M Private Placement of Units With Warrants; Up to $21.7M More Possible - TradingView
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies - The Manila Times
CervoMed (NASDAQ: CRVO) secures $10.5M financing to extend cash runway into 2027 - Stock Titan
CervoMed shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
CervoMed Shareholders Back Board, Pay and Incentive Plan - TipRanks
CervoMed shareholders approve board elections and key proposals at annual meeting - Investing.com
CervoMed (NASDAQ: CRVO) logs 67% turnout, backs 2026 proposals - Stock Titan
CRVO Q1 2026 Earnings: Wider-than-Expected Loss on No Revenue; Stock Slightly DownEarnings Decline Risk - newsline.com
CRVO Q1 2026 Earnings: EPS Misses Estimates as Clinical‑Stage Biotech Maintains R&D FocusPositive Surprise Momentum - newsline.com
CervoMed Inc. (CRVO) Edges Lower as Stock Tests Support Near $3.00Trend Following Picks - The Legal Advocate
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CervoMed Inc. (CRVO) Hovers Near Key Support After Marginal DeclineHedge Fund Exposure - newsline.com
CRVO Q1 2026 Earnings: EPS Misses EstimatesEarnings Revision Report - The Legal Advocate
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueTrough Earnings Signal - The Legal Advocate
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cervomed Inc 주식 (CRVO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 17 '25 |
Buy |
8.43 |
3,500 |
29,505 |
13,500 |
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
2.60%
0.94%
자본화:
|
볼륨(24시간):